A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives

A clinical view on BET inhibition in CKD  CVD Understanding recent data and future perspectives
10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Kamyar Kalantar-Zadeh, MD - Irvine, CA, USA
  • Overview

    Kalantar shares data that suggest that epigenetic modification with the BET inhibitor apabetalone may improve factors involved in the pathogenesis of CKD, including alkaline phosphatase.

  • Educational information

    This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.

  • Faculty

    Kamyar Kalantar-Zadeh, MD, MPH, PhD, is a specialist in Nephrology and Professor of Medicine and Public Health at UC Irvine School of Medicine.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free